This Review outlines the understanding and management of triple-negative breast cancer (TNBC). TNBC shares morphological and genetic abnormalities with basal-like breast cancer (BLBC), a subgroup of breast cancer defined by gene-expression profiling. However, TNBC and BLBC tumors are heterogeneous and overlap is incomplete. Breast cancers found in BRCA1 mutation carriers are also frequently triple negative and basal like. TNBC and BLBC occur most frequently in young women, especially African Americans, and tend to exhibit aggressive, metastatic behavior. These tumors respond to conventional chemotherapy but relapse more frequently than hormone receptor-positive, luminal subtypes and have a worse prognosis. New systemic therapies are urgently needed as most patients with TNBC and/or BLBC relapse with distant metastases, and hormonal therapies and HER2-targeted agents are ineffective in this group of tumors. Poly (ADP-ribose) polymerase inhibitors, angiogenesis inhibitors, EGFR-targeted agents, and src kinase and mTOR inhibitors are among the therapeutic agents being actively investigated in clinical trials in patients with TNBC and/or BRCA1-associated tumors. Increased understanding of the genetic abnormalities involved in the pathogenesis of TNBC, BLBC and BRCA1-associated tumors is opening up new therapeutic possibilities for these hard-to-treat breast cancers.
Triple-negative breast cancer (TNBC), a subgroup that lacks expression of hormone receptors and HER2, overlaps with basal-like breast cancer (BLBC), a subgroup that expresses cytokeratins and other non-luminal (basal) genes
Breast cancers occurring in patients with germline BRCA1 mutations are often triple negative and basal like, and BRCA1 defects or deficiency may be involved in sporadic TNBC and BLBC
Although heterogeneous, TNBCs and BLBCs typically occur in younger women, and are associated with a range of adverse biological features including high grade, high mitotic count and p53 positivity
Although responsive to chemotherapy, TNBCs and BLBCs tend to relapse and metastasize early and have a worse prognosis than other tumor subtypes
There are no specific therapies for patients with TNBC or BLBC; new treatments under investigation include novel cytotoxics, poly (ADP-ribose) polymerase inhibitors, angiogenesis inhibitors, EGFR-targeted agents, and src kinase inhibitors
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Reis-Filho, J. S. & Tutt, A. N. J. Triple negative tumours: a critical review. Histopathology 52, 108–118 (2008).
Viale, G. et al. Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat. 116, 317–328 (2009).
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a lpopulation-based study from the California Cancer Registry. Cancer 109, 1721–1728 (2007).
Morris, G. J. et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110, 876–884 (2007).
Kyndi, M. et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 26, 1419–1426 (2008).
Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
Rakha, E. A. et al. Prognostic markers in triple-negative breast cancer. Cancer 109, 25–32 (2007).
Tan, D. S. P. et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 111, 27–44 (2008).
Cheang, M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14, 1368–1376 (2008).
Kreike, B. et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9, R65 (2007).
Weigelt, B. et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216, 141–150 (2008).
Carey, L. A. et al. Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials [abstract]. Cancer Res. 69 (Suppl.), a2014 (2009).
Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006).
Sasa, M., Bando, Y., Takahashi, M., Hirose, T. & Nagao, T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J. Surg. Oncol. 97, 30–34 (2008).
Dabbs, D. J., Chivukula, M., Carter, G. & Bhargava, R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod. Pathol. 19, 1506–1511 (2006).
Van de Rijn, M. et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 161, 1991–1996 (2002).
Shin, B. K. et al. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncol. Rep. 19, 617–625 (2008).
Tsutsui, S., Ohno, S., Murakami, S., Hachitanda, Y. & Oda, S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res. Treat. 71, 67–75 (2002).
Boström, P. et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res. Notes 17, 140 (2009).
Voduc, D., Nielsen, T. O., Cheang, M. C. & Foulkes, W. D. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum. Pathol. 39, 1431–1437 (2008).
Westfall, M. D. & Pietenpol, J. A. p63: Molecular complexity in development and cancer. Carcinogenesis 25, 857–864 (2004).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
Herschkowitz, J. I. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76 (2007).
Charafe-Jauffret, E. et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25, 2273–2284 (2006).
Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
Nielsen, T. O. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367–5374 (2004).
Gusterson, B. A., Ross, D. T., Heath, V. J. & Stein, T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 7, 143–148 (2005).
Lakhani, S. R. & O'Hare, M. J. The mammary myoepithelial cell--Cinderella or ugly sister? Breast Cancer Res. 3, 1–4 (2001).
Palacios, J. et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am. J. Pathol. 146, 605–612 (1995).
Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393–10398 (2003).
Moyano, J. V. et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 116, 261–270 (2006).
Shien, T. et al. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation. J. Clin. Pathol. 58, 1299–1304 (2005).
Abd El-Rehim, D. M. et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 203, 661–671 (2004).
Bertolo, C. et al. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am. J. Clin. Pathol. 130, 414–424 (2008).
Rodriguez-Pinilla, S. M. et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 12, 1533–1539 (2006).
Jones, C. et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin. Cancer Res. 10, 5988–5997 (2004).
Liu, H., Fan, Q., Zhang, Z., Yu, H. & Meng, F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum. Pathol. 39, 167–174 (2008).
Livasy, C. A. et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 19, 264–271 (2006).
Waddell, N. et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res. Treat. doi:10.1007/s10549-009-0653-1.
Richardson, A. L. et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121–132 (2006).
Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814–819 (2004).
Korsching, E. et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J. Pathol. 206, 451–457 (2005).
Korsching, E. et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab. Invest. 82, 1525–1533 (2002).
Herschkowitz, J. I., He, X., Fan, C. & Perou, C. M. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 10, R75 (2008).
Sarrió, D. et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68, 989–997 (2008).
Vincent-Salomon, A. & Thiery, J. P. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 5, 101–106 (2003).
Petersen, O. W. et al. The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion. Breast Cancer Res. 3, 213–217 (2001).
Jones, C. et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 64, 3037–3045 (2004).
Gordon, L. A. et al. Breast cell invasive potential relates to the myoepithelial phenotype. Int. J. Cancer 106, 8–16 (2003).
Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106, 13820–13825 (2009).
Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116–4124 (2009).
Deugnier, M. A. et al. EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties. J. Cell Biol. 159, 453–463 (2002).
Kim, M. J. et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 37, 1217–1226 (2006).
Reis-Filho, J. S. et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl. Immunohistochem. Mol. Morphol. 11, 1–8 (2003).
Jacquemier, J. et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J. Pathol. 207, 260–268 (2005).
Van Laere, S. J. et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res. Treat. 95, 243–255 (2006).
Bertucci, F. et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 65, 2170–2178 (2005).
Adélaïde, J. et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 67, 11565–11575 (2007).
Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529–541 (2006).
Melchor, L. et al. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27, 3165–3175 (2008).
Chin, S. F. et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 8, R215 (2007).
Rakha, E. A. & Ellis, I. O. Triple-negative/basal-like breast cancer: review. Pathology 41, 40–47 (2009).
Rakha, E. A. et al. Are triple negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 9, 404 (2007).
Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678–5685 (2005).
Banerjee, S. et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 59, 729–735 (2006).
Rakha, E. A. et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 15, 2302–2310 (2009).
Van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
Foulkes, W. D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95, 1482–1485 (2003).
Lakhani, S. R. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11, 5175–5180 (2005).
Lidereau, R. et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 60, 1206–1210 (2000).
Stefansson, O. A. et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 11, R47 (2009).
Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785–3790 (2008).
Carey, L. A. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J. Clin. Oncol. 28, 361–363 (2010).
Alli, E., Sharma, V. B., Sunderesakumar, P. & Ford, J. M. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 69, 3589–3596 (2009).
Rakha, E. A. et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum. Pathol. 39, 857–865 (2008).
Turner, N. C. et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26, 2126–2132 (2007).
Matros, E. et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res. Treat. 91, 179–186 (2005).
Perreard, L. et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 8, R23 (2006).
Tang, P., Wang, J. & Bourne, P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum. Pathol. 39, 506–513 (2008).
Harris, L. N. et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 8, R66 (2006).
Stead, L. A. et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 11, R18 (2009).
Huo, D. et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J. Clin. Oncol. 27, 4515–4521 (2009).
Yin, W. J. et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res. Treat. 115, 325–333 (2009).
Lin, C. et al. Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9, 192 (2009).
Kurebayashi, J. et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16 (Suppl. 2), S72–S77 (2007).
Lund, M. J. et al. Molecular differences between the triple negative tumors of African-American women and white women [abstract]. San Antonio Breast Cancer Symp. a2087 (2008).
Millikan, R. C. et al. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat. 109, 123–139 (2008).
Liu, B. et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8, 2031–2040 (2009).
Jiralerspong, S. et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27, 3297–3302 (2009).
Goodwin, P. J., Ligibel, J. A. & Stambolic, V. Metformin in breast cancer: time for action. J. Clin. Oncol. 27, 3271–3273 (2009).
Dolle, J. M. et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol. Biomarkers Prev. 18, 1157–1166 (2009).
Foulkes, W. D. et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98, 1569–1577 (2003).
Uematsu, T., Kasami, M. & Yuen, S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 250, 638–647 (2009).
Lin, N. U. et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113, 2638–2645 (2008).
Minn, A. J. et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl Acad. Sci. USA 104, 6740–6745 (2007).
Jumppanen, M. et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 9, R16 (2007).
Nguyen, P. L. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 26, 2373–2378 (2008).
Voduc, K. D. et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684–1691 (2010).
Berry, D. A. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295, 1658–1667 (2006).
Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329–2334 (2007).
Tanner, M. et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24, 2428–2436 (2006).
Troester, M. A. et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 64, 4218–4226 (2004).
Falo, C. et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. J. Cancer Res. Clin. Oncol. 133, 423–429 (2007).
Cheang, M. et al. Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a519 (2009).
Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G. & Harkin, D. P. The role of BRCA1 in the cellular response to chemotherapy. J. Natl Cancer Inst. 96, 1659–1668 (2004).
Byrski, T. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115, 359–363 (2009).
Sirohi, B. et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 19, 1847–1852 (2008).
Uhm, J. E. et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int. J. Cancer 124, 1457–1462 (2009).
Silver, D. P. et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145–1153 (2010).
Delaloge, S. et al. Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER−, PR−, HER2−), HER2+++, or BRCA 1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts) [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a1010 (2009).
Denduluri, N. & Swain, S. M. Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin. Investig. Drugs 17, 423–435 (2008).
Rugo, H. S. et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies [abstract]. San Antonio Breast Cancer Symp. a3057 (2008).
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293–301 (2010).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Plummer, R. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917–7923 (2008).
Plummer, R. et al. First and final report of a phase II study of the poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) [abstract]. J. Clin. Oncol. 24 (18 Suppl.), a8013 (2006).
Kopetz, S. et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a3577 (2008).
Mahany, J. J. et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a3579 (2008).
O'Shaughnessy, J. et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [abstract]. J. Clin. Oncol. 26 (Suppl.), a3 (2009).
Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).
Gelmon, K. A. et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a3002 (2010).
Isakoff, S. J. et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a1019 (2010).
Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239–3247 (2010).
Ryan, P. D. et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a551 (2009).
Burstein, H. J. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26, 1810–1816 (2008).
Bhargava, R. et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 18, 1027–1033 (2005).
Reis-Filho, J. S. et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 209, 445–453 (2006).
Nechushtan, H., Steinberg, H. & Peretz, T. Prelimenary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients [abstract]. J. Clin. Oncol. 27 (15 Suppl.), e12018 (2009).
Carey, L. A. et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J. Clin. Oncol. 26 (Suppl.), a1009 (2008).
O'Shaughnessy, J. et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstract 308]. Breast Cancer Res. Treat. 106 (Suppl. 1), S32 (2007).
Verbeek, B. S. et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 180, 383–388 (1996).
Hiscox, S. et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97, 263–274 (2006).
Finn, R. S. et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 105, 319–326 (2007).
Finn, R. S. et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059 [abstract]. San Antonio Breast Cancer Symp. a3118 (2008).
Savage, K. et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 13, 90–101 (2007).
Savage, K. et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res. Treat. 110, 245–256 (2008).
Farmer, P. et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660–4671 (2005).
Agoff, S. N., Swanson, P. E., Linden, H., Hawes, S. E. & Lawton, T. J. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120, 725–731 (2003).
We would like to thank C. Barton (consultant of Fondazione Michelangelo, the non-profit organization that organized the seminar on TNBC) for assistance in preparing the manuscript.
E. Winer has received grants or research support from Genentech. D. Cameron acts as a consultant for and has received research support from Pfizer and Roche and is a consultant for Sanofi-Aventis. L. Gianni acts as a consultant for Biogen Idec, Eisai, Genentech, GlaxoSmithKline, Millennium Pharmaceuticals, Novartis, Roche and Sanofi-Aventis. L. Carey and G. Viale declare no competing interests.
About this article
Cite this article
Carey, L., Winer, E., Viale, G. et al. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 7, 683–692 (2010). https://doi.org/10.1038/nrclinonc.2010.154
Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling
Breast Cancer Research and Treatment (2021)
The Cancer Journal (2021)
MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple negative breast cancer cell proliferation and chemoresistance
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
Molecular Cancer Therapeutics (2021)